Cailleteau, A.; Ferrer, L.; Geffroy, D.; Fleury, V.; Lalire, P.; Doré, M.; Rousseau, C.
Are Dual-Phase 18F-Fluorodeoxyglucose PET-mpMRI Diagnostic Performances to Distinguish Brain Tumour Radionecrosis/Recurrence after Cranial Radiotherapy Usable in Routine? Cancers 2024, 16, 3216.
https://doi.org/10.3390/cancers16183216
AMA Style
Cailleteau A, Ferrer L, Geffroy D, Fleury V, Lalire P, Doré M, Rousseau C.
Are Dual-Phase 18F-Fluorodeoxyglucose PET-mpMRI Diagnostic Performances to Distinguish Brain Tumour Radionecrosis/Recurrence after Cranial Radiotherapy Usable in Routine? Cancers. 2024; 16(18):3216.
https://doi.org/10.3390/cancers16183216
Chicago/Turabian Style
Cailleteau, Axel, Ludovic Ferrer, Delphine Geffroy, Vincent Fleury, Paul Lalire, Mélanie Doré, and Caroline Rousseau.
2024. "Are Dual-Phase 18F-Fluorodeoxyglucose PET-mpMRI Diagnostic Performances to Distinguish Brain Tumour Radionecrosis/Recurrence after Cranial Radiotherapy Usable in Routine?" Cancers 16, no. 18: 3216.
https://doi.org/10.3390/cancers16183216
APA Style
Cailleteau, A., Ferrer, L., Geffroy, D., Fleury, V., Lalire, P., Doré, M., & Rousseau, C.
(2024). Are Dual-Phase 18F-Fluorodeoxyglucose PET-mpMRI Diagnostic Performances to Distinguish Brain Tumour Radionecrosis/Recurrence after Cranial Radiotherapy Usable in Routine? Cancers, 16(18), 3216.
https://doi.org/10.3390/cancers16183216
